TrialNature communications2023

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.

Yue Hu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.